{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T17:32:03Z","timestamp":1786555923547,"version":"build-2736575974"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.leukres.2026.108283","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T07:43:10Z","timestamp":1784533390000},"page":"108283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Dose schedule modifications of 5-azacitidine monotherapy in myelodysplastic neoplasias and chronic myelomonocytic leukaemia"],"prefix":"10.1016","volume":"168","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0416-8420","authenticated-orcid":false,"given":"Gerasimos","family":"Tsilimidos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ribal","family":"Bou Mjahed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Germing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Blum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.leukres.2026.108283_bib1","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/BF02135399","article-title":"5-Azacytidine, a new, highly effective cancerostatic","volume":"20","author":"Sorm","year":"1964","journal-title":"Experientia"},{"issue":"7","key":"10.1016\/j.leukres.2026.108283_bib2","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1038\/s41375-021-01218-0","article-title":"Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies","volume":"35","author":"Stomper","year":"2021","journal-title":"Leukemia"},{"issue":"35","key":"10.1016\/j.leukres.2026.108283_bib3","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1038\/sj.onc.1205699","article-title":"5-Azacytidine and 5-aza-2\u2032-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy","volume":"21","author":"Christman","year":"2002","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.leukres.2026.108283_bib4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ijc.23607","article-title":"Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine","volume":"123","author":"Stresemann","year":"2008","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.leukres.2026.108283_bib5","first-page":"1453","article-title":"The disposition and pharmacokinetics in humans of 5-azacytidine administered intravenously as a bolus or by continuous infusion","volume":"36","author":"Israili","year":"1976","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.leukres.2026.108283_bib6","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1177\/0091270004271947","article-title":"Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes","volume":"45","author":"Marcucci","year":"2005","journal-title":"J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.leukres.2026.108283_bib7","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/MPH.0b013e31805d8f21","article-title":"Azacitidine pharmacokinetics in an adolescent patient with renal compromise","volume":"29","author":"Tsao","year":"2007","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.leukres.2026.108283_bib8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13148-016-0237-y","article-title":"A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers","volume":"8","author":"Diesch","year":"2016","journal-title":"Clin. Epigenet."},{"issue":"9","key":"10.1016\/j.leukres.2026.108283_bib9","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1111\/j.1349-7006.2011.01993.x","article-title":"Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes","volume":"102","author":"Uchida","year":"2011","journal-title":"Cancer Sci."},{"issue":"9","key":"10.1016\/j.leukres.2026.108283_bib10","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1038\/leu.2008.145","article-title":"A pilot pharmacokinetic study of oral azacitidine","volume":"22","author":"Garcia-Manero","year":"2008","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.leukres.2026.108283_bib11","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/ajco.12835","article-title":"Efficacy, safety and pharmacokinetics of subcutaneous azacitidine in Chinese patients with higher risk myelodysplastic syndromes: results from a multicenter, single-arm, open-label phase 2 study","volume":"14","author":"Du","year":"2018","journal-title":"Asia Pac. J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.leukres.2026.108283_bib12","doi-asserted-by":"crossref","first-page":"e430","DOI":"10.1111\/ajco.12659","article-title":"Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher-risk myelodysplastic syndromes","volume":"13","author":"Chou","year":"2017","journal-title":"Asia Pac. J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.leukres.2026.108283_bib13","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1182\/blood.V48.3.331.331","article-title":"5-Azacytidine (NSC 102816): a new drug for the treatment of myeloblastic leukemia","volume":"48","author":"Vogler","year":"1976","journal-title":"Blood"},{"issue":"7-8","key":"10.1016\/j.leukres.2026.108283_bib14","first-page":"807","article-title":"Sequentially administered 5-azacitidine and amsacrine in refractory adult acute leukemia: a phase I-II trial of the Southeastern Cancer Study Group","volume":"69","author":"Winton","year":"1985","journal-title":"Cancer Treat. Rep."},{"issue":"4","key":"10.1016\/j.leukres.2026.108283_bib15","first-page":"339","article-title":"Feasibility and efficacy of 5-azacytidine used early in the therapy of adult acute nonlymphocytic leukemia: an ECOG pilot study","volume":"2","author":"Cassileth","year":"1979","journal-title":"Cancer Clin. Trials"},{"issue":"1","key":"10.1016\/j.leukres.2026.108283_bib16","first-page":"21","article-title":"Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes","volume":"7","author":"Silverman","year":"1993","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.leukres.2026.108283_bib17","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/ajh.2830370207","article-title":"Evaluation of continuous infusion low-dose 5-azacytidine in the treatment of myelodysplastic syndromes","volume":"37","author":"Chitambar","year":"1991","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2026.108283_bib18","first-page":"A12","article-title":"Azacitidine in myelodysplastic syndromes: CALGB studies 8421 and 8921","volume":"68","author":"Silverman","year":"1994","journal-title":"Ann. Hematol."},{"issue":"10","key":"10.1016\/j.leukres.2026.108283_bib19","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.leukres.2026.108283_bib20","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1182\/blood-2018-10-844696","article-title":"Treatment of MDS","volume":"133","author":"Platzbecker","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2026.108283_bib21","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.leukres.2026.108283_bib22","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2141.2010.08082.x","article-title":"Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C","volume":"149","author":"Fenaux","year":"2010","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.leukres.2026.108283_bib23","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3324\/haematol.2012.074831","article-title":"A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial","volume":"98","author":"Gore","year":"2013","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.leukres.2026.108283_bib24","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.critrevonc.2010.04.005","article-title":"Effects of azacitidine compared with conventional care regimens in elderly (>\/= 75 years) patients with higher-risk myelodysplastic syndromes","volume":"76","author":"Seymour","year":"2010","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"3","key":"10.1016\/j.leukres.2026.108283_bib25","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/bjh.16680","article-title":"Azacitidine in patients older than 80 years with acute myeloid leukaemia or myelodysplastic syndromes: a report on 115 patients","volume":"190","author":"Peterlin","year":"2020","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.leukres.2026.108283_bib26","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.3109\/10428194.2013.834532","article-title":"Results of treatment with azacitidine in patients aged >\/= 75 years included in the Spanish Registry of Myelodysplastic Syndromes","volume":"55","author":"Xicoy","year":"2014","journal-title":"Leuk. Lymphoma"},{"issue":"6","key":"10.1016\/j.leukres.2026.108283_bib27","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/bjh.17062","article-title":"The effect of 5-azacytidine treatment delays and dose reductions on the prognosis of patients with myelodysplastic syndrome: how to optimize treatment results and outcomes","volume":"192","author":"Diamantopoulos","year":"2021","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.leukres.2026.108283_bib28","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1179\/2295333714Y.0000000102","article-title":"Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey","volume":"70","author":"Beguin","year":"2015","journal-title":"Acta Clin. Belg."},{"issue":"5","key":"10.1016\/j.leukres.2026.108283_bib29","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/ajh.23677","article-title":"Real-life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile","volume":"89","author":"Breccia","year":"2014","journal-title":"Am. J. Hematol."},{"issue":"12","key":"10.1016\/j.leukres.2026.108283_bib30","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1002\/cncr.33472","article-title":"Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice","volume":"127","author":"Clavio","year":"2021","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.leukres.2026.108283_bib31","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00277-010-0921-5","article-title":"Predictive value of pretreatment risk group and baseline LDH levels in MDS patients receiving azacitidine treatment","volume":"89","author":"Moon","year":"2010","journal-title":"Ann. Hematol."},{"issue":"4","key":"10.1016\/j.leukres.2026.108283_bib32","doi-asserted-by":"crossref","first-page":"887","DOI":"10.3109\/10428194.2014.935366","article-title":"Patients with myelodysplastic syndromes treated with azacitidine in clinical practice: the AVIDA registry","volume":"56","author":"Grinblatt","year":"2015","journal-title":"Leuk. Lymphoma"},{"issue":"3","key":"10.1016\/j.leukres.2026.108283_bib33","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s12253-018-00574-0","article-title":"Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia","volume":"25","author":"Helbig","year":"2019","journal-title":"Pathol. Oncol. Res."},{"issue":"6","key":"10.1016\/j.leukres.2026.108283_bib34","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/bjh.15273","article-title":"Azacitidine in the 'real-world': an evaluation of 1101 higher-risk myelodysplastic syndrome\/low blast count acute myeloid leukaemia patients in Ontario, Canada","volume":"181","author":"Mozessohn","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"12","key":"10.1016\/j.leukres.2026.108283_bib35","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2026.108283_bib36","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/cncr.24894","article-title":"Azacitidine for the treatment of lower risk myelodysplastic syndromes: a retrospective study of 74 patients enrolled in an Italian named patient program","volume":"116","author":"Musto","year":"2010","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.leukres.2026.108283_bib37","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1111\/cas.13739","article-title":"Five-day regimen of azacitidine for lower-risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): a prospective single-arm phase 2 trial","volume":"109","author":"Morita","year":"2018","journal-title":"Cancer Sci."},{"issue":"12","key":"10.1016\/j.leukres.2026.108283_bib38","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1158\/1078-0432.CCR-12-3540","article-title":"Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and\/or erythropoietin unresponsive patients with low\/INT-1-risk myelodysplastic syndromes","volume":"19","author":"Fili","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.leukres.2026.108283_bib39","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1080\/10428194.2017.1366998","article-title":"Prospective randomized trial of 5 days azacitidine versus supportive care in patients with lower-risk myelodysplastic syndromes without 5q deletion and transfusion-dependent anemia","volume":"59","author":"Sanchez-Garcia","year":"2018","journal-title":"Leuk. Lymphoma"},{"issue":"9","key":"10.1016\/j.leukres.2026.108283_bib40","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/ajh.21482","article-title":"A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes","volume":"84","author":"Martin","year":"2009","journal-title":"Am. J. Hematol."},{"issue":"13","key":"10.1016\/j.leukres.2026.108283_bib41","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1182\/blood-2017-06-788497","article-title":"Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS\/MPN","volume":"130","author":"Jabbour","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108283_bib42","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12878-016-0049-5","volume":"16","author":"Garcia-Manero","year":"2016","journal-title":"BMC Hematol."},{"issue":"7","key":"10.1016\/j.leukres.2026.108283_bib43","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.leukres.2014.03.004","article-title":"Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia","volume":"38","author":"Garcia-Delgado","year":"2014","journal-title":"Leuk. Res."},{"issue":"8","key":"10.1016\/j.leukres.2026.108283_bib44","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.3109\/10428194.2012.660632","article-title":"5-azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials","volume":"53","author":"Breccia","year":"2012","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.leukres.2026.108283_bib45","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1179\/1607845415Y.0000000039","article-title":"Treatment with 5-Azacytidine improves clinical outcome in high-risk MDS patients in the 'real life' setting: a single center observational study","volume":"21","author":"Papageorgiou","year":"2016","journal-title":"Hematology"},{"issue":"8","key":"10.1016\/j.leukres.2026.108283_bib46","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1007\/s00277-019-03724-9","article-title":"Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice","volume":"98","author":"Scalzulli","year":"2019","journal-title":"Ann. Hematol."},{"issue":"11","key":"10.1016\/j.leukres.2026.108283_bib47","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1200\/JCO.2008.17.1058","article-title":"Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes","volume":"27","author":"Lyons","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.leukres.2026.108283_bib48","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/j.clml.2023.09.010","article-title":"Full-dose azacitidine in 5 Days Versus 7 Days with a weekend break in myelodysplastic syndromes: a retrospective cohort study","volume":"24","author":"Sapinho","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"3","key":"10.1016\/j.leukres.2026.108283_bib49","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/ejh.12709","article-title":"Efficacy and safety of a 5-day regimen of azacitidine for patients with high-risk myelodysplastic syndromes","volume":"97","author":"Fujimaki","year":"2016","journal-title":"Eur. J. Haematol."},{"issue":"9","key":"10.1016\/j.leukres.2026.108283_bib50","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1038\/leu.2015.115","article-title":"Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry","volume":"29","author":"Bernal","year":"2015","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.leukres.2026.108283_bib51","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/ejh.12595","article-title":"Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia","volume":"96","author":"Voso","year":"2016","journal-title":"Eur. J. Haematol."},{"issue":"9","key":"10.1016\/j.leukres.2026.108283_bib52","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s00277-013-1762-9","article-title":"Efficacy and tolerability of 5-day azacytidine dose-intensified regimen in higher-risk MDS","volume":"92","author":"Pierdomenico","year":"2013","journal-title":"Ann. Hematol."},{"issue":"6","key":"10.1016\/j.leukres.2026.108283_bib53","doi-asserted-by":"crossref","DOI":"10.1002\/jha2.70185","article-title":"Alternative 5-azacitidine 5-Day 100 mg\/m(2) Dosage Shows Non-Inferiority to Classical Schedule for Myelodysplastic Neoplasm (MDS) and Chronic Myelomonocytic Leukaemia (CMML) Treatment","volume":"6","author":"Tsilimidos","year":"2025","journal-title":"EJHaem"},{"issue":"4","key":"10.1016\/j.leukres.2026.108283_bib54","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.3324\/haematol.2018.203885","article-title":"A phase II study of the efficacy and safety of an intensified schedule of azacytidine in intermediate-2 and high-risk patients with myelodysplastic syndromes: a study by the Groupe Francophone des Myelodysplasies (GFM)","volume":"104","author":"Ades","year":"2019","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.leukres.2026.108283_bib55","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1365-2141.2011.08893.x","volume":"155","author":"van der Helm","year":"2011","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.leukres.2026.108283_bib56","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00277-009-0824-5","article-title":"Reduction of 5-azacitidine induced skin reactions in MDS patients with evening primrose oil","volume":"89","author":"Platzbecker","year":"2010","journal-title":"Ann. Hematol."},{"issue":"6","key":"10.1016\/j.leukres.2026.108283_bib57","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1016\/j.clml.2015.02.030","article-title":"Higher infection rate after 7- compared with 5-day cycle of azacitidine in patients with higher-risk myelodysplastic syndrome","volume":"15","author":"Ofran","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"7","key":"10.1016\/j.leukres.2026.108283_bib58","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s00277-017-3001-2","article-title":"A retrospective study evaluating the impact of infectious complications during azacitidine treatment","volume":"96","author":"Schuck","year":"2017","journal-title":"Ann. Hematol."},{"issue":"8","key":"10.1016\/j.leukres.2026.108283_bib59","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.leukres.2013.05.005","article-title":"Safety and efficacy of 5-azacytidine treatment in myelodysplastic syndrome patients with moderate and mild renal impairment","volume":"37","author":"Douvali","year":"2013","journal-title":"Leuk. Res."},{"issue":"7","key":"10.1016\/j.leukres.2026.108283_bib60","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.leukres.2026.108283_bib61","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/leu.2014.85","article-title":"A multi-centre phase 2 study of azacitidine in chronic myelomonocytic leukaemia","volume":"28","author":"Drummond","year":"2014","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.leukres.2026.108283_bib62","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1002\/cncr.25759","article-title":"Activity of azacitidine in chronic myelomonocytic leukemia","volume":"117","author":"Costa","year":"2011","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.leukres.2026.108283_bib63","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.leukres.2013.01.004","article-title":"Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine","volume":"37","author":"Ades","year":"2013","journal-title":"Leuk. Res."},{"issue":"7","key":"10.1016\/j.leukres.2026.108283_bib64","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/ajh.25488","article-title":"Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients","volume":"94","author":"Coston","year":"2019","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2026.108283_bib65","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ebiom.2018.04.018","article-title":"Prognostic role of gene mutations in chronic myelomonocytic leukemia patients treated with hypomethylating agents","volume":"31","author":"Duchmann","year":"2018","journal-title":"EBioMedicine"},{"issue":"4","key":"10.1016\/j.leukres.2026.108283_bib66","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.leukres.2014.01.006","article-title":"Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival","volume":"38","author":"Pleyer","year":"2014","journal-title":"Leuk. Res."},{"issue":"10","key":"10.1016\/j.leukres.2026.108283_bib67","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1200\/JCO.22.00437","article-title":"Decitabine versus hydroxyurea for advanced proliferative chronic myelomonocytic leukemia: results of a randomized Phase III trial within the EMSCO network","volume":"41","author":"Itzykson","year":"2023","journal-title":"J. Clin. Oncol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521262600127X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521262600127X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T16:37:23Z","timestamp":1786552643000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521262600127X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":67,"alternative-id":["S014521262600127X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108283","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dose schedule modifications of 5-azacitidine monotherapy in myelodysplastic neoplasias and chronic myelomonocytic leukaemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108283","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108283"}}